Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Adrenal tracer uptake by 18F-FDOPA PET/CT in patients with pheochromocytoma and controls.

Noordzij W, Glaudemans AWJM, Schaafsma M, van der Horst-Schrivers ANA, Slart RHJA, van Beek AP, Kerstens MN.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1560-1566. doi: 10.1007/s00259-019-04332-5. Epub 2019 Apr 22.

2.

Bortezomib based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.

Minnema MC, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma PF, Kröger N, Wu KL, Kersten MJ, Schaafsma MR, Croockewit S, de Waal E, Zweegman S, Tick L, Broijl A, Koene H, Bos G, Sonneveld P, Schönland S.

Haematologica. 2019 Mar 28. pii: haematol.2018.213900. doi: 10.3324/haematol.2018.213900. [Epub ahead of print]

3.

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, Levin MD; HOVON CLL study group.

Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. Epub 2018 Aug 16.

4.

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.

Stevens-Kroef MJ, Olde Weghuis D, ElIdrissi-Zaynoun N, van der Reijden B, Cremers EMP, Alhan C, Westers TM, Visser-Wisselaar HA, Chitu DA, Cunha SM, Vellenga E, Klein SK, Wijermans P, de Greef GE, Schaafsma MR, Muus P, Ossenkoppele GJ, van de Loosdrecht AA, Jansen JH.

Genes Chromosomes Cancer. 2017 Jul;56(7):524-534. doi: 10.1002/gcc.22455. Epub 2017 Mar 31.

PMID:
28236351
5.

A systematic review of the reliability and validity of discrete choice experiments in valuing non-market environmental goods.

Rakotonarivo OS, Schaafsma M, Hockley N.

J Environ Manage. 2016 Dec 1;183:98-109. doi: 10.1016/j.jenvman.2016.08.032. Epub 2016 Aug 27. Review.

6.

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.

Doorduijn JK, van Imhoff GW, van der Holt B, Schouten HC, Schaafsma MR, MacKenzie MA, Baars JW, Kersten MJ, Lugtenburg PJ, van den Bent MJ, Enting RH, Spoelstra FM, Poortmans P, Bromberg JEC.

Hematol Oncol. 2017 Dec;35(4):497-503. doi: 10.1002/hon.2342. Epub 2016 Aug 17.

PMID:
27530779
7.

Enhanced THz extinction in arrays of resonant semiconductor particles.

Schaafsma MC, Georgiou G, Rivas JG.

Opt Express. 2015 Sep 21;23(19):24440-55. doi: 10.1364/OE.23.024440.

PMID:
26406649
8.

Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study.

Holtzer-Goor KM, Schaafsma MR, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Uyl-de Groot CA.

Qual Life Res. 2015 Dec;24(12):2895-906. doi: 10.1007/s11136-015-1039-y. Epub 2015 Jul 24.

9.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J, Beverloo HB, Valk PJ, van Marwijk Kooy M, Wijermans PW, Schaafsma MR, Biemond BJ, Vekemans MC, Breems DA, Verdonck LF, Fey MF, Jongen-Lavrencic M, Janssen JJ, Huls G, Kuball J, Pabst T, Graux C, Schouten HC, Gratwohl A, Vellenga E, Ossenkoppele G, Löwenberg B; HOVON; SAKK Leukemia Groups.

Leukemia. 2015 May;29(5):1041-50. doi: 10.1038/leu.2014.332. Epub 2014 Nov 27.

PMID:
25428261
10.

Active terahertz beam steering by photo-generated graded index gratings in thin semiconductor films.

Steinbusch TP, Tyagi HK, Schaafsma MC, Georgiou G, Gómez Rivas J.

Opt Express. 2014 Nov 3;22(22):26559-71. doi: 10.1364/OE.22.026559.

PMID:
25401807
11.

New insights into phosphorus mobilisation from sulphur-rich sediments: time-dependent effects of salinisation.

van Diggelen JM, Lamers LP, van Dijk G, Schaafsma MJ, Roelofs JG, Smolders AJ.

PLoS One. 2014 Nov 4;9(11):e111106. doi: 10.1371/journal.pone.0111106. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0118387.

12.

Hepatocellular carcinoma after danazol treatment for hereditary angio-oedema.

Berkel AE, Bouman DE, Schaafsma MR, Verhoef C, Klaase JM.

Neth J Med. 2014 Sep;72(7):380-2.

13.

Coastal Zone Ecosystem Services: from science to values and decision making; a case study.

Luisetti T, Turner RK, Jickells T, Andrews J, Elliott M, Schaafsma M, Beaumont N, Malcolm S, Burdon D, Adams C, Watts W.

Sci Total Environ. 2014 Sep 15;493:682-93. doi: 10.1016/j.scitotenv.2014.05.099. Epub 2014 Jul 1.

PMID:
24992461
14.

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.

Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, José Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M.

Am J Hematol. 2014 Apr;89(4):355-62. doi: 10.1002/ajh.23641. Epub 2014 Feb 5.

15.

Real-world costs of chronic lymphocytic leukaemia in the Netherlands.

Holtzer-Goor KM, Bouwmans-Frijters CA, Schaafsma MR, de Weerdt O, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Groot CA.

Leuk Res. 2014 Jan;38(1):84-90. doi: 10.1016/j.leukres.2013.10.029. Epub 2013 Nov 8.

PMID:
24268350
16.

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.

Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30.

17.

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, San Miguel J, Sonneveld P, Palumbo A.

Haematologica. 2013 Jun;98(6):980-7. doi: 10.3324/haematol.2012.075051. Epub 2013 Feb 26.

18.

Selective detection of bacterial layers with terahertz plasmonic antennas.

Berrier A, Schaafsma MC, Nonglaton G, Bergquist J, Rivas JG.

Biomed Opt Express. 2012 Nov 1;3(11):2937-49. doi: 10.1364/BOE.3.002937. Epub 2012 Oct 23.

19.

Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.

Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld P.

Haematologica. 2013 Jan;98(1):87-94. doi: 10.3324/haematol.2012.067058. Epub 2012 Aug 8.

20.

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM.

J Clin Oncol. 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820. Epub 2012 Jul 16. Erratum in: J Clin Oncol. 2012 Oct 10;30(29):3654.

PMID:
22802322
21.

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network.

Blood. 2011 Aug 4;118(5):1239-47. doi: 10.1182/blood-2011-03-341669. Epub 2011 Jun 13.

22.

Universal scaling of the figure of merit of plasmonic sensors.

Offermans P, Schaafsma MC, Rodriguez SR, Zhang Y, Crego-Calama M, Brongersma SH, Gómez Rivas J.

ACS Nano. 2011 Jun 28;5(6):5151-7. doi: 10.1021/nn201227b. Epub 2011 May 20.

PMID:
21574624
23.

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.

Verelst SG, Termorshuizen F, Uyl-de Groot CA, Schaafsma MR, Ammerlaan AH, Wittebol S, Sinnige HA, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst HM, Sonneveld P, Wijermans PW; Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON).

Ann Hematol. 2011 Dec;90(12):1427-39. doi: 10.1007/s00277-011-1224-1. Epub 2011 Apr 7.

PMID:
21472373
24.

The effectiveness of strategies to change organisational culture to improve healthcare performance: a systematic review.

Parmelli E, Flodgren G, Beyer F, Baillie N, Schaafsma ME, Eccles MP.

Implement Sci. 2011 Apr 3;6:33. doi: 10.1186/1748-5908-6-33. Review.

25.

Cytarabine dose for acute myeloid leukemia.

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

N Engl J Med. 2011 Mar 17;364(11):1027-36. doi: 10.1056/NEJMoa1010222.

26.

Decision tables and rule engines in organ allocation systems for optimal transparency and flexibility.

Schaafsma M, van der Deijl W, Smits JM, Rahmel AO, de Vries Robbé PF, Hoitsma AJ.

Transpl Int. 2011 May;24(5):433-40. doi: 10.1111/j.1432-2277.2011.01221.x. Epub 2011 Feb 3.

27.

The effectiveness of strategies to change organisational culture to improve healthcare performance.

Parmelli E, Flodgren G, Schaafsma ME, Baillie N, Beyer FR, Eccles MP.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD008315. doi: 10.1002/14651858.CD008315.pub2. Review.

28.

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.

Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst H, Sonneveld P; Dutch-Belgium Cooperative Group HOVON.

J Clin Oncol. 2010 Jul 1;28(19):3160-6. doi: 10.1200/JCO.2009.26.1610. Epub 2010 Jun 1.

PMID:
20516439
29.

Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.

Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, Minnema MC, van Oers MH, Raymakers RA, Schaafsma MR, Vellenga E, Wijermans PW, Wittebol S, Sonneveld P, Zweegman S.

Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):138-43. doi: 10.3816/CLML.2010.n.020.

PMID:
20371448
30.

Subjective cognitive complaints at menopause associated with declines in performance of verbal memory and attentional processes.

Schaafsma M, Homewood J, Taylor A.

Climacteric. 2010 Feb;13(1):84-98. doi: 10.3109/13697130903009187.

PMID:
19722118
31.

Change processes in couple therapy: an intensive case analysis of one couple using a common factors lens.

Blow AJ, Morrison NC, Tamaren K, Wright K, Schaafsma M, Nadaud A.

J Marital Fam Ther. 2009 Jul;35(3):350-68. doi: 10.1111/j.1752-0606.2009.00122.x.

PMID:
19522787
32.

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.

Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC, Ossenkoppele G, Sonneveld P, Maertens J, van Marwijk Kooy M, Schaafsma MR, Wijermans PW, Biesma DH, Wittebol S, Voogt PJ, Baars JW, Zachée P, Verdonck LF, Löwenberg B, Dekker AW; Dutch-Belgian HOVON Cooperative Group.

Blood. 2009 Feb 5;113(6):1375-82. doi: 10.1182/blood-2008-07-168625. Epub 2008 Nov 6.

33.

[Que sera].

Buitenhuis CP, Schaafsma M, Austie BA, Maaskant A, de Swart FE, van der Bijl-Custers SE, Brummelhuis-Thybaut MP, Ramaker-Schutte J, Melchior MB, Boezeman MA, Van Dieten S.

Tijdschr Diergeneeskd. 2008 Sep 1;133(17):729. Dutch. No abstract available.

PMID:
18807622
34.

Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.

Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoe GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Westveer PH, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Haematologica. 2007 Jul;92(7):928-35.

35.

Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene.

van Bergen CA, Kester MG, Jedema I, Heemskerk MH, van Luxemburg-Heijs SA, Kloosterboer FM, Marijt WA, de Ru AH, Schaafsma MR, Willemze R, van Veelen PA, Falkenburg JH.

Blood. 2007 May 1;109(9):4089-96. Epub 2007 Jan 18.

36.

Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer.

Slager EH, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Kloosterboer FM, Kester MG, Jedema I, Marijt WA, Schaafsma MR, Willemze R, Falkenburg JH.

Blood. 2006 Jun 15;107(12):4954-60. Epub 2006 Feb 23.

37.

Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.

van Agthoven M, Kramer MH, Sonneveld P, van der Hem KG, Huijgens PC, Wijermans PW, Kluin-Nelemans HC, Schaafsma MR, Biesma DH, Mattijssen V, Uyl-de Groot CA, Hagenbeek A.

Haematologica. 2005 Oct;90(10):1422-32.

38.

Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation.

Hoogendoorn M, Olde Wolbers J, Smit WM, Schaafsma MR, Jedema I, Barge RM, Willemze R, Falkenburg JH.

Clin Cancer Res. 2005 Jul 15;11(14):5310-8.

39.

Economic assessment on the management of chronic lymphocytic leukaemia.

Goor KM, Schaafsma MR, Huijgens PC, van Agthoven M.

Expert Opin Pharmacother. 2005 Jun;6(7):1179-89. Review.

PMID:
15957971
40.
41.

The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.

Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, Schaafsma MR, Westveer PH, Peters GJ, Noordhuis P, Muus P, Selleslag D, van der Holt B, Delforge M, Löwenberg B, Verhoef GE; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Blood. 2004 Apr 15;103(8):2908-13. Epub 2003 Dec 4. Erratum in: Blood. 2004 Jul 1;104(1):42.

42.

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.

Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GE, Steijaert MM, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P.

J Clin Oncol. 2003 Aug 15;21(16):3041-50.

PMID:
12915593
43.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.

Blood. 2003 Mar 15;101(6):2144-51. Epub 2002 Nov 27.

44.

[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].

Wu KL, Schaafsma MR, Lokhorst HM, Wijermans PW, van der Holt B, Sonneveld P.

Ned Tijdschr Geneeskd. 2002 Aug 3;146(31):1445-8. Dutch.

PMID:
12190011
45.

Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients.

Richel DJ, Johnsen HE, Canon J, Guillaume T, Schaafsma MR, Schenkeveld C, Hansen SW, McNiece I, Gringeri AJ, Briddell R, Ewen C, Davies R, Freeman J, Miltenyi S, Symann M.

Bone Marrow Transplant. 2000 Feb;25(3):243-9.

46.

Vulvar paraneoplastic amyloidosis with the appearance of a vulvar carcinoma.

Persoons JH, Sutorius FJ, Koopman RJ, Schaafsma MR, van Doorn GA.

Am J Obstet Gynecol. 1999 Apr;180(4):1041-4.

PMID:
10203681
47.

Photosensitive seizures associated with interferon alfa-2a.

Brouwers PJ, Bosker RJ, Schaafsma MR, Wilts G, Neef C.

Ann Pharmacother. 1999 Jan;33(1):113-4. No abstract available.

PMID:
9972396
48.

Ex vivo evidence of lymphocyte apoptosis in hairy cell leukemia, induced by 2-chlorodeoxyadenosine treatment.

Idink-Mecking CA, Richel DJ, Vermes I, Schaafsma MR, Reutelingsperger C, Haanen C.

Ann Hematol. 1998 Jan;76(1):25-9.

PMID:
9486921
49.

Apoptosis and secondary necrosis of lymphocytes in culture.

Vermes I, Haanen C, Richel DJ, Schaafsma MR, Kalsbeek-Batenburg E, Reutelingsperger CP.

Acta Haematol. 1997;98(1):8-13.

PMID:
9210907
50.

Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.

Guchelaar HJ, Richel DJ, Schaafsma MR.

Ann Hematol. 1994 Nov;69(5):223-30. Review.

PMID:
7948311

Supplemental Content

Loading ...
Support Center